Evodiamine (Isoevodiamine) suppresses non-small cell lung cancer by promoting the elevation of CD8+ T cells and concurrently downregulating the MUC1-C/PD-L1 axis [59]. This evidence concerns the gene MUC1 and non-small cell lung carcinoma.